Premium
Docosahexaenoic and eicosapentaenoic acid supplementation reduces growth of basal‐like and claudin‐low breast cancer subtypes in obese mice
Author(s) -
Ford Nikki Ann,
Barnett Kelsey,
Hursting Stephen D
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.863.15
Subject(s) - docosahexaenoic acid , eicosapentaenoic acid , wnt signaling pathway , breast cancer , medicine , endocrinology , mammary tumor , apoptosis , cancer , cancer research , fatty acid , biology , polyunsaturated fatty acid , biochemistry , signal transduction
The prescription drug Lovaza® contains ethyl esters of the marine based omega 3 fatty acids docosahexaenoic acid (DHA; 38% w/w) and eicosapentanoic acid (EPA; 47%) which play major roles in inflammation, cell membrane fluidity and cell signaling. The effects of omega‐3 fatty acid supplementation on ER‐negative basal‐like and claudin‐low breast tumors, which are aggressive subtypes with poor prognoses, are not well characterized. Furthermore, the ability of EPA and DHA to offset the enhancing effects of obesity on these cancers is unknown. Female C57BL/6 mice were fed either a control (AIN‐76A) diet, diet‐induced obesity regimen (DIO; 60 kcal % fat diet), or DIO diet + Lovaza (2.5g / kg) for 6 weeks. All mice were then orthotopically injected with a tumor cell suspension derived from MMTV‐Wnt‐1 mammary tumors (Wnt‐1 basal‐like) or a clonal isolate from the same tumors shown to have a molecular profile similar to human claudin‐low breat tumors (M‐Wnt claudin low). Tumors were allowed to grow until one or more tumors reached 1 cm in diameter in any direction and then mice were killed and tumors were paraffin embedded or snap frozen for further analysis. Wnt‐1 and M‐Wnt mammary tumor weight was significantly reduced by Lovaza supplementation in obese mice in parallel with enhanced cellular apoptosis. This work was supported by a Breast Cancer Research Foundation Grant and Glaxo‐Smith Kline donated the Lovaza® capsules. Grant Funding Source : Breast Cancer Research Fund